Market research
4575.TSE CanBas Co., Ltd
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 16B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.83
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3244570002
- Market cap
- 16B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.83
About
About CanBas Co., Ltd
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4575.TSE discussion.
5 years, 6 months ago
CanBas Co., Ltd is currently in a long term downtrend where the price is trading 23.0% below its 200 day moving average.
From a valuation standpoint, the stock is 55.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.3.
CanBas Co., Ltd's total revenue rose by 0.0% to $28M since the same quarter in the previous year.
Its net income has increased by 21.6% to $-100M since the same quarter in the previous year.
Based on the above factors, CanBas Co., Ltd gets an overall score of 3/5.